A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Early or Locally Advanced Breast Cancer
Interventions: DRUG: Herceptin (trastuzuamb)|DRUG: SB3 (proposed trastuzumab biosimilar)
Sponsor: Samsung Bioepis Co., Ltd.